KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to -$22.4 million.

  • Halozyme Therapeutics' Cash from Financing Activities fell 22069.39% to -$22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$571.1 million, marking a year-over-year decrease of 15683.06%. This contributed to the annual value of -$218.9 million for FY2024, which is 4635.59% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Cash from Financing Activities of -$22.4 million as of Q3 2025, which was down 22069.39% from -$299.0 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash from Financing Activities registered a high of $367.8 million during Q2 2022, and its lowest value of -$299.0 million during Q2 2025.
  • Its 5-year average for Cash from Financing Activities is -$26.9 million, with a median of -$3.3 million in 2025.
  • In the last 5 years, Halozyme Therapeutics' Cash from Financing Activities surged by 92181.11% in 2022 and then crashed by 2648044.87% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Cash from Financing Activities (Quarter) stood at -$156.0 million in 2021, then soared by 104.06% to $6.3 million in 2022, then crashed by 4048.81% to -$249.9 million in 2023, then grew by 1.4% to -$246.4 million in 2024, then skyrocketed by 90.91% to -$22.4 million in 2025.
  • Its last three reported values are -$22.4 million in Q3 2025, -$299.0 million for Q2 2025, and -$3.3 million during Q1 2025.